Table 6. Studies of IORT in Retroperitoneal sarcoma.
| Author/Year | Sample size | Study design | IORT type | IORT dose (Gy) | EBRT % | Median follow-up | LC 5 year (%) | OS 5 year (%) | Toxicity grade 3 or > |
|---|---|---|---|---|---|---|---|---|---|
| Sindelar et al. [86] 1993 | 35 GTR-100% |
RCT Sx + IORT + low-dose PORT Vs Sx + high-dose PORT |
IOERT | 20 | 100 | 96 | IORT + PORT- 60%’ PORT-20% |
- | Neuropathy IORT + PORT-60% PORT-5% Enteritis IORT + PORT-13% PORT-50% |
| Alektiar et al. [87] 2000 | 32 Recurrent -62%, GTR-94% |
Retrospective cohort | HDR-IORT | 12–15 | 78 | 33 | 62 | 45 | GI -18% Neuropathy-0% |
| Gieschen et al. [88] 2001 | 37 IORT-20 No IORT-17 Recurrent-22% GTR-78% |
Retrospective cohort | IOERT | 10–20 |
100 100 |
38 |
IORT-83 No IORT-61 p = 0.197¥ |
IORT-74 No IORT-30 p = 0.044¥ |
Total-20% Neuropathy-1* Fistula-2* |
| Peterson et al [89] 2002 | 87 Recurrent-50%, GTR-84% |
Retrospective cohort | IOERT | 8.75–30 | 89 | 42 | 59 | 47 | GI-14% Neuropathy- 10% |
| Bobin et al. [90] 2003 | 24 Recurrent-79% GTR-92 |
Retrospective cohort | IOERT | 8–22 | 92 | 53 | 46 | 56 | Total-8% Neuropathy-2* |
| Pierie et al. [91] 2006 | IORT-14 No IORT-27 Recurrent-0% GTR-100% |
Retrospective cohort | IOERT | 10–20 | 100 100 |
27 | NR | IORT-77 No IORT-45 p = 0.38 |
GI-1% Neuropathy-3% |
| Krempien et al. [92] 2006 | 67 Recurrent-61%, GTR-82% |
Retrospective cohort | IOERT | 12–20 | 67 | 30 | 40 | 64 R0:87 R+:50 p < 0.01 |
Fistula-3* Neuropathy-5* Urethral stenosis-2* |
| Pawlik et al. [93] 2006 | 72 IORT-22 No IORT-50 Recurrent-25%, GTR-75% |
Prospective cohort | IOERT | 15 | 100 | 40 | 60¥ | 50 | NR |
| Ballo et al. [94] 2007 | 83 IORT-18 No IORT-63 Recurrent-28%, R+-47% |
Retrospective cohort | IOERT | 10–15 | 100 | 47 |
IORT-46 No IORT-51 p = 0.9 |
NR | NR |
| Dziewirski et al. [95] 2010 | 57 Recurrent -74%, GTR-85% |
Prospective cohort | HDR-IORT | 20 | 60 | 20 | 51 | 55 | NR |
| Sweeting et al. [96] 2013 | 18 Recurrent-28%, GTR-100% |
Retrospective cohort | IOERT | 10–20 | 94 | 43 | 64 | 72 | NR |
| Roeder et al. [97] 2014 | 27 Recurrent-15%, GTR-100% |
Prospective cohort | IOERT | 10–20 | 100 | 33 | 72 | 74 | Total-6% late toxicity |
| Stucky et al. [98] 2014 | 63 IORT-37 Sx only-26 Recurrent-36%,GTR-89% |
Retrospective cohort | IOERT | 10–20 |
100 0 |
45 |
IORT-89 Sx-46 p = 0.03 |
IORT-60 No IORT-60 |
Ureteral stricture-1 No grade-3 neuropathy |
| Gronchi et al. [99] 2014 | 83 IORT-14pts only Recurrent-24% GTR-84% |
Prospective cohort | IOERT | 10–12 | 88 | 58 | 63 | 59 | NR |
RCT: randomised control trial, PORT: post-operative RT, Sx: surgery, LC: local control, OS: overall survival, DFS: disease-free survival, NR: not reported,
*
Number of patients
¥
In GTR patients,
α-crude rate